Abstract 15094: In Patients on Warfarin, Does a History of Depression Impact Time in Therapeutic Range and Subsequent Dementia Risk?

• Published in: Circulation (New York, N.Y.) N.Y.), 2020-11, Vol.142 (Suppl_3 Suppl 3), p.A15094-A15094
• Main Authors: Knight, Stacey, May, Heidi T, Woller, Scott, Stevens, Scott, McCubrey, Raymond O, Bair, Tami L, Anderson, Jeffrey L, Muhlestein, Joseph B, Bunch, T Jared J
• Format: Article
• Language: English
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/circ.142.suppl_3.15094

ObjectiveBoth time in therapeutic range (TTR) for anticoagulation and depression are associated with dementia risk. However, it is unknown if depression impacts TTR or their combined effect on dementia risk. MethodsWe studied 14,953 patients who were chronically anticoagulated with warfarin (target INR 2-3) for atrial fibrillation (AF), venous thromboembolism (VTE), or a mechanical heart valve and managed by the Intermountain Healthcare Clinical Pharmacist Anticoagulation Service from 2003 to 2015. We excluded patients with a diagnosis of dementia before or within the first six months of warfarin management. TTR was evaluated as a continuous variable and by categories≤25%, 26-50%, 51-75%, and >75%. We examined the association of depression to TTR using finite mixture modeling and utilized multivariable Cox hazard regression to determine the association of TTR and depression to 3-year dementia incidence. ResultsForty percent (n=6055) of patients were diagnosed with depression while on warfarin therapy. Patients with depression were younger, female, taking warfarin for VTE, and had more comorbidities. They also had a lower TTR compared to patients without depression; after adjustment for baseline differences, depressed patients had an average TTR decrease of 4% (p